|
Neural Interfaces Conference
|
Meeting/ Workshop
|
FDA
|
NIBIB, CSR, NEI, NIA, NICHD, NIDCD, NINDS, OD
|
The Neural Interfaces research community consists of investigators, supported by grants or contracts, who are working in areas that include functional neuromuscular/electrical stimulation, auditory prosthesis, cortical prosthesis, neuromodulation, microelectrode array technology, brain computer/machine interfaces and other related areas. This conference was held in June of 2010. NIH Program Officers reviewed abstracts.
|
|
Newborn Screening Coding and Terminology Guide
|
Resource Development
|
CDC, HRSA, OS
|
NLM, NHGRI, NICHD
|
This ongoing collaboration develops, supplements and publicizes a free online resource with guidance to help promote efficient electronic exchange of standardized newborn screening data. Related efforts include: studying the screening process for diseases including severe combined immunodeficiency (SCID), lysosomal storage disorders (LSDs), and critical congenital heart disease (CCHD), and developing standard codes for ordering and reporting the results of newborn screening for SCID, CCHD, and other conditions added to the Uniform Recommended Screening Panel by the Secretary''s Advisory Committee on Heritable Disorders in Newborns and Children.
|
|
Newborn Screening Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC, HRSA
|
NICHD, NHLBI, NLM
|
The NIH, HRSA, CDC, the American College of Medical Genetics and the Genetic Alliance meet monthly, in person or online, to discuss and coordinate current activities and initiatives in newborn screening. Topics include the activities of the Newborn Screening Translational Research Network Coordinating Center, the Clearinghouse for Newborn Screening information, Sickle Cell Screening Programs, the CDC Quality Control program for Newborn Screening, and the Regional Newborn Screening Collaboratives.
|
|
NIDA Consultative Assistance to the FDA Regarding Domestic Scheduling of New Medications
|
Other
|
FDA
|
NIDA
|
Subsequent to the filing of a New Drug Application by a pharmaceutical company, the FDA prepares an “8-factor analysis” of abuse liability and prepares a draft scheduling recommendation. NIDA reviews the draft documents and provides advice regarding potential revisions.
|
|
NIH American Association for Clinical Chemistry (AACC) Statistics and Experimental Design Workshop
|
Meeting/ Workshop
|
FDA
|
NCI, NHLBI
|
Stakeholders in the disease biomarker community gathered to discuss statistical design of biomarker discovery experiments and verification experiments.
|
|
NIH Consensus Development Conference: Diagnosing Gestational Diabetes Mellitus
|
Meeting/ Workshop
|
AHRQ, CDC
|
OD, NICHD, NIDDK, NINR
|
Gestational diabetes mellitus (GDM) is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy (especially during the third trimester of pregnancy). GDM is estimated to occur in 1-14% of U.S. pregnancies, affecting more than 200,000 women annually. It is one of the most common disorders in pregnancy and is associated with an increased risk of complications for the mother and child. Debate continues regarding the choice of tests and the effectiveness of treatment, especially in women with mild to moderate glucose intolerance. To better understand the benefits and risks of various GDM screening and diagnostic approaches, the NIH engaged in a rigorous assessment of the available scientific evidence. An evidence report on GDM will be prepared, and a Consensus Development Conference will be held on October 29–31, 2012
|
|
NIH Consensus Development Conference: Inhaled Nitric Oxide Therapy for Premature Infants
|
Meeting/ Workshop
|
AHRQ, CDC
|
OD, NHLBI, NICHD
|
The final product of an NIH Consensus Conference is a written statement on a controversial medical topic prepared by an independent panel of health professionals free from conflicts of interest on the basis of the results of a systematic literature review, presentations by experts in the field, and public comments and questions. Inhaled nitric oxide therapy was approved by the U.S. Food and Drug Administration in 2000 to treat term and near-term infants with respiratory failure. Since its approval, researchers have examined expanding the use of inhaled nitric oxide therapy to treat premature babies born at less than 34 weeks gestation. Studies to evaluate its safety and efficacy for these infants have had mixed results in terms of key outcomes. The goal of this conference was to clarify the role of inhaled nitric oxide in this population. The meeting was held on October 27-29, 2010.
|
|
NIH Recombinant DNA Advisory Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NCI, NHGRI, NIAID, NINDS
|
Advises NIH on the safe and ethical conduct of basic and clinical research involving recombinant DNA.
|
|
NIH State-of-the-Science Conference: Role of Active Surveillance in the Management of Men With Localized Prostate Cancer
|
Meeting/ Workshop
|
AHRQ, CDC
|
OD, NCI
|
Prostate cancer is the second leading cause of cancer-related deaths among men in the United States. It is estimated that in 2010, approximately 32,000 American men died of prostate cancer and 218,000 were newly diagnosed with the disease. Most prostate cancers are detected by a blood test that measures prostate-specific antigen (PSA), a tumor marker. More than half of cancers detected with PSA screening are localized (confined to the prostate), not aggressive at diagnosis, and unlikely to become life-threatening. However, 90 percent of patients receive immediate treatment for prostate cancer, such as surgery or radiation therapy. In many patients, these treatments have substantial short- and long-term side effects without any clinical benefit. Appropriate management of screen-detected, early-stage, low-risk prostate cancer is an important public health issue given the number of men affected and the risk for adverse outcomes, such as diminished sexual function and loss of urinary control. To better understand the benefits and risks of active surveillance and other observational management strategies for PSA-screening-detected, low-grade, localized prostate cancer, the NIH engaged in a rigorous assessment of the available scientific evidence. After weighing the evidence, an unbiased, independent panel prepared and presented a statement addressing the key questions. The conference was held December 5-7, 2011.
|
|
NIH Translational Research Interest Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, CC, CIT, CSR, NCCAM, NCATS, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD
|
As Chair of the NIH Translational Research Interest Group (TRIG), the NCI staff has coordinated Forums, Workshops, NIH Bench-to-Bedside Awardees’ Lecture Series, and Monthly Seminar Series to help bridge the gap between laboratory research and clinical applications; suggestions of topics and speakers for the Annual NIH Research Festivals; and nominations of speakers for the NIH Wednesday Afternoon Lecture Series and the NIH Director’s Lecture Series. The NCI staff has informed the TRIG members of scientific events coordinated with other NIH Scientific Interest Groups and Working Groups.
|